| | 149709-62-6 Basic information More.. |
| Product Name: | AHU-377 | | Synonyms: | 4-(((2R,4R)-1-([1,1'-biphenyl]-4-yl)-5-ethoxy-4-Methyl-5-oxopentan-2-yl)aMino)-4-oxobutanoic acid;AHU-377;4-(((2S,4R)-1-([1,1'-biphenyl]-4-yl)-5-ethoxy-4-Methyl-5-oxopentan-2-yl)aMino)-4-oxobutanoic acid;(2R,4S)-5-(Biphenyl-4-yl)-4-[(3-carboxypropionyl)amino]-2-methylpentanoic acid ethyl ester;AHU-377,149709-62-6;4-[[(2S,4R)-5-ethoxy-4-methyl-5-oxo-1-(4-phenylphenyl)pentan-2-yl]amino]-4-oxobutanoic acid;4-{[(2S,4R)-1-(4-Biphenylyl)-5-ethoxy-4-methyl-5-oxo-2-pentanyl]amino}-4-oxobutanoic acid;AHU-77 | | CAS: | 149709-62-6 | | MF: | C24H29NO5 | | MW: | 411.49 | | EINECS: | 1592732-453-0 | | Mol File: | 149709-62-6.mol |  |
Use
According to a recent study published by Novartis, LCZ696, a cardiovascular drug being developed by the company, will become a new hope for the company. The current study shows that this drug functions well in the remission of cardiovascular necrosis and other symptoms caused by heart disease.
LCZ696 is a combination of Novartis Diovan and AHU-377. Some analysts have spoken highly of the drug and estimated that it might be submitted to the FDA as early as next year. Once confirmed in the audit it will mark another great step forward of Novartis in the field of cardiovascular drugs.
Although it showed high expectations to LCZ696, Novartis still has a long way to go, given the setbacks of its serelaxin in the FDA and the European Medicines Administration.
The news came straight from Basel as investigators around the world were wrapping up the big scientific meeting of the American College of Cardiology.
- AHU-377
-
- US $0.00-0.00 / KG
- 2022-09-30
- CAS:149709-62-6
- Min. Order: 1KG
- Purity: 98%
- Supply Ability: 1ton
- AHU-377
-
- US $5.99 / KG
- 2022-02-25
- CAS:149709-62-6
- Min. Order: 1KG
- Purity: 99%
- Supply Ability: 100KG
|
|
149709-62-6
Recommend Suppliers |
|